|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Net product sales | |||||
| Collaboration revenues | |||||
| Total revenues | |||||
| Operating expenses: | |||||
| Cost of revenues | |||||
| Research and development | |||||
| Acquired in-process research and development | |||||
| Selling, general, and administrative | |||||
| Total operating expenses | |||||
| Operating income | |||||
| Other income (expense): | |||||
| Interest expense | |||||
| Unrealized (loss) gain on equity investments | |||||
| Loss on extinguishment of convertible senior notes | |||||
| Charges associated with convertible senior notes | |||||
| Investment income and other, net | |||||
| Total other income (expense), net | |||||
| Income before provision for income taxes | |||||
| Provision for income taxes | |||||
| Net income | |||||
| Foreign currency translation adjustments, net of tax | |||||
| Unrealized gain (loss) on available-for-sale debt securities, net of tax | |||||
| Comprehensive income | |||||
| Earnings per share, basic (in USD per share) | |||||
| Earnings per share, diluted (in USD per share) | |||||
| Weighted average common shares outstanding, basic (in shares) | |||||
| Weighted average common shares outstanding, diluted (in shares) | |||||
Loading...